Perseus Proteomics, Inc. 4882

TSE · Japan · Health Technology

¥161.00-5.00 (-3.01%)

Market closed· Oct 2, 2026, 6:30 AM UTC· JPY · Data may be delayed

Company news

Yahoo FinanceApr 22, 2026

Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight

The polycythemia vera market is set for expansion by 2036, as new entrants such as Protagonist Therapeutics and Takeda Pharmaceuticals (rusfertide), Merck (bomedemstat), Italfarmaco (givinostat), Ionis Pharmaceuticals and Ono Pharmaceutical (sapablursen), Silence Therapeutics (Divesiran (SLN124)), Perseus Proteomics (PPMX-T003), Disc Medicines (DISC-3405), and others are evaluating their lead candidates in different stages of clinical development, respectively.New York, USA, April 22, 2026 (GLOB

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.

Prices may be delayed and are for informational purposes only - not investment advice.